Rabacfosadine

N/A

Report date: 2023/02/18 22:37:19
NME

Base Information

Drug NameRabacfosadine
Drug Alias Name雷巴沙定rabacfosadinumrabacfosadine雷巴萨定rabacfosadina +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionApoptosis stimulantsDNA synthesis inhibitors
TargetsNot applicable
Therapy Area/IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaUnited StatesRussian Federation
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGilead Sciences Inc
Active IndicationsN/A
Inactive IndicationsMultiple MyelomaLymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksKEGG